Girish Nair is a Cardiology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8333 Naab Rd Ste 420
Indianapolis, IN 462601992
Telephone
317-338-6666Provider last certified this registry record 27 Jul 2022.
Clinical trials
- Randomized Controlled Trial- Ablation Strategy for Paroxysmal Atrial Fibrillation - Trigger and Substrate Guided Wide Area Radiofrequency Ablation Compared to Pulsed Field Ablation Pulmonary Vein Isolation
Sponsor: Ottawa Heart Institute Research Corporation
- Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2
Sponsor: Corewell Health East
- Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
Sponsor: Corewell Health East
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20255 payments
- Boston Scientific CorporationProgram year20255 payments
- Biosense Webster, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
71.9%Beta blocker31.6%Metoprolol Succinate59%Sotalol17%Carvedilol10%Metoprolol Tartrate9%Bisoprolol Fumarate3%Nebivolol Hcl1%Propranolol Hcl Er1%Part D<11 patientsAntiarrhythmic12.7%Amiodarone Hcl53%Flecainide Acetate17%Mexiletine Hcl11%Dofetilide9%Propafenone Hcl6%Multaq4%Part D<11 patients+ 11 more classes in this area
Blood & clotting
26.4%Factor Xa inhibitor24.2%Eliquis90%Xarelto10%Part D≥194 patientsVitamin K antagonist1.4%Warfarin Sodium100%Part D≥15 patients+ 1 more class in this area
Metabolism & gastrointestinal
1.7%SGLT2 inhibitor1%Jardiance100%Part D≥11 patientsPotassium supplement0.8%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”